168 related articles for article (PubMed ID: 16403216)
21. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling.
Bhuiyan MA; Ishiguro M; Hossain M; Nakamura T; Ozaki M; Miura S; Nagatomo T
Life Sci; 2009 Jul; 85(3-4):136-40. PubMed ID: 19446572
[TBL] [Abstract][Full Text] [Related]
22. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis.
Heublein S; Mayr D; Meindl A; Kircher A; Jeschke U; Ditsch N
J Exp Clin Cancer Res; 2017 Apr; 36(1):57. PubMed ID: 28427429
[TBL] [Abstract][Full Text] [Related]
23. Angiotensin II induces peroxisome proliferator-activated receptor gamma in PC12W cells via angiotensin type 2 receptor activation.
Zhao Y; Foryst-Ludwig A; Bruemmer D; Culman J; Bader M; Unger T; Kintscher U
J Neurochem; 2005 Sep; 94(5):1395-401. PubMed ID: 15992368
[TBL] [Abstract][Full Text] [Related]
24. Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8.
Senda A; Mukai Y; Toda T; Hayakawa T; Yamashita M; Eliasson E; Rane A; Inotsume N
Biol Pharm Bull; 2015; 38(12):1975-9. PubMed ID: 26632190
[TBL] [Abstract][Full Text] [Related]
25. Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes.
Kamiyama E; Yoshigae Y; Kasuya A; Takei M; Kurihara A; Ikeda T
Drug Metab Pharmacokinet; 2007 Aug; 22(4):267-75. PubMed ID: 17827781
[TBL] [Abstract][Full Text] [Related]
26. Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes.
Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):239-245. PubMed ID: 28374982
[TBL] [Abstract][Full Text] [Related]
27. The impact of peroxisome proliferator-activated receptor-γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy.
Chiang CH; Chang YC; Wang SS; Chen YJ; See XY; Peng CY; Hsia YP; Chiang CH; Chiang CH; Peng CM
Cancer Med; 2023 Apr; 12(8):9583-9588. PubMed ID: 36825549
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic effects of candesartan in inflammatory skin disorders by suppressing Th17 differentiation.
Son SE; Im DS
Int Immunopharmacol; 2023 Nov; 124(Pt B):110995. PubMed ID: 37801970
[TBL] [Abstract][Full Text] [Related]
29. Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARg.
Zhang J; Hao QQ; Liu X; Jing Z; Jia WQ; Wang SQ; Xu WR; Cheng XC; Wang RL
Oncotarget; 2017 Apr; 8(15):25612-25627. PubMed ID: 28445965
[TBL] [Abstract][Full Text] [Related]
30. Photosensitivity with Angiotensin II Receptor Blockers: A Retrospective Study Using Data from VigiBase(®).
Viola E; Coggiola Pittoni A; Drahos A; Moretti U; Conforti A
Drug Saf; 2015 Oct; 38(10):889-94. PubMed ID: 26187686
[TBL] [Abstract][Full Text] [Related]
31. Peroxisome proliferator-activated receptor (PPAR) and vitamin D receptor (VDR) signaling pathways in melanoma cells: promising new therapeutic targets?
Sertznig P; Seifert M; Tilgen W; Reichrath J
J Steroid Biochem Mol Biol; 2010 Jul; 121(1-2):383-6. PubMed ID: 20214982
[TBL] [Abstract][Full Text] [Related]
32. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.
Miura S; Nakao N; Hanzawa H; Matsuo Y; Saku K; Karnik SS
PLoS One; 2013; 8(11):e79914. PubMed ID: 24260317
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade.
Schmidt B; Drexler H; Schieffer B
Am J Cardiovasc Drugs; 2004; 4(6):361-8. PubMed ID: 15554721
[TBL] [Abstract][Full Text] [Related]
34. Telmisartan inhibits human urological cancer cell growth through early apoptosis.
Matsuyama M; Funao K; Kuratsukuri K; Tanaka T; Kawahito Y; Sano H; Chargui J; Touraine JL; Yoshimura N; Yoshimura R
Exp Ther Med; 2010 Mar; 1(2):301-306. PubMed ID: 22993542
[TBL] [Abstract][Full Text] [Related]
35. Differential effects of angiotensin II type I receptor blockers on reducing intraocular pressure and TGFβ signaling in the mouse retina.
Hazlewood RJ; Chen Q; Clark FK; Kuchtey J; Kuchtey RW
PLoS One; 2018; 13(8):e0201719. PubMed ID: 30092004
[TBL] [Abstract][Full Text] [Related]
36. Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450.
Yang R; Luo Z; Liu Y; Sun M; Zheng L; Chen Y; Li Y; Wang H; Chen L; Wu M; Zhao H
Curr Drug Metab; 2016; 17(7):681-91. PubMed ID: 27216792
[TBL] [Abstract][Full Text] [Related]
37. Inhibiting angiotensin type 1 receptors as a target for diabetes.
Kintscher U; Foryst-Ludwig A; Unger T
Expert Opin Ther Targets; 2008 Oct; 12(10):1257-63. PubMed ID: 18781824
[TBL] [Abstract][Full Text] [Related]
38. Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator.
Hamano Y; Okude T; Yokosuka O; Ogawa M
Nephron Extra; 2011 Jan; 1(1):78-90. PubMed ID: 22470382
[TBL] [Abstract][Full Text] [Related]
39. Effects of selected triorganotin compounds on transcriptional activity of vitamin D3 receptor and peroxisome proliferator-activated receptor gamma.
Toporova L; Illes P; Dvorak Z; Bobal P; Otevrel J; Brtko J
Gen Physiol Biophys; 2018 Sep; 37(5):589-596. PubMed ID: 30307405
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
